Title: Project Manager
Specifications: Permanent – Full Time
Salary: £42,000 per Annum
Location: UK/ London Remote Based Role
Directorate: CEOO
Closing date: 15 January, 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

To support the Evidence Production and Methods Department (EPM), Publishing and Technology department (P&T), Cochrane Library Product Manager and other Central Executive Teams (CET) in delivering on high priority projects: to project manage the highest priority EPM, P&T and other Cochrane projects where appropriate.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
• A flexible work environment.
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• Further information on the role and how to apply
• The deadline to receive your application is 15th January, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Wednesday, January 3, 2024 Category: Jobs

Cochrane warmly invites you to submit abstracts for oral presentations, posters, and workshops for the second Global Evidence Summit (GES) 2024. Hosted by global leaders in evidence synthesis and evidence-based practice, including Cochrane, JBI, Guidelines International Network (GIN), and The Campbell Collaboration, the summit is set to take place in the historical city of Prague, Czech Republic, from 10 to 13 September 2024, with satellite meetings on 9 September 2024.

This collaborative effort between esteemed organizations represents a unique opportunity for professionals across various sectors, such as health, education, social justice, the environment, and climate change, to engage in discussions about producing, summarizing, and disseminating evidence to inform policy and practice. Abstract and workshop submissions will be accepted until the extended deadline of  6 March 2024.

Dr. Karla Soares-Weiser, Vice Chair of the GES Scientific Committee and Cochrane Editor in Chief, extends an invitation to the Cochrane community, emphasizing the importance of their participation in this global event: 

As we open the doors for abstract submissions to the second Global Evidence Summit, I am thrilled to invite the Cochrane community to contribute to the exchange of ideas that will shape the future of evidence-based practice. This summit, uniting leading organizations in evidence synthesis, is a testament to our commitment to improving lives worldwide through the power of credible evidence. I encourage all Cochrane members and supporters to submit their abstracts for oral presentations, posters, or workshops, and join us in Prague for this exceptional opportunity to collaborate, learn, and drive positive change.

The themes for GES 2024 include:

• Sustainable development agenda
• The importance of research integrity making evidence accessible
• Power of synergy in evidence synthesis & synthesis products
• Evidence translation & implementation
• Advocating for greater evidence communication & use of evidence
• From global evidence to local impact
  
  
  
  

Catherine Spencer, Cochrane's CEO, emphasizing the significance of the GES in fostering synergies and knowledge sharing within the global evidence community:

Our recent Cochrane Colloquium in London was a testament to the vibrant spirit of the Cochrane community. In 2024, we are excited to co-host the second Global Evidence Summit alongside our esteemed partners. GES provides a crucial platform to address vital issues across sectors, while showcasing the incredible methods and work of Cochrane. I warmly invite all Cochrane members to participate actively and submit abstracts. Let's unite for #GES2024 and contribute to advancing evidence-based practice globally!

Abstracts and workshop submissions are open until 6 March 2024 with notifications of acceptances happening on 30 April 2024. 

• Oral and poster abstract details
• Workshop submission details
• Visit the GES Website

Thursday, February 29, 2024

Four global leaders in evidence synthesis and evidence-based practice, Cochrane, JBI, Guidelines International Network, and The Campbell Collaboration, invite you to join the eagerly anticipated 2nd Global Evidence Summit. These organizations are forgoing their annual conferences in 2024, and uniting once again to provide an event with a unique opportunity to exchange ideas about how best to produce, summarise and disseminate evidence to inform policy and practice, and use that evidence to improve people’s lives across the world. 

Hosted in the historical city of Prague, Czech Republic
at the stunning, modern O2 universum venue
on 10-13 September with satellite meetings on 9 September 2024

The summit will be multi-disciplinary and will bring together academics, researchers, and leaders across different sectors, including health, education, social justice, the environment, and climate change. Abstract and workshop submissions will open in early January. The themes for GES 2024 are:

• Sustainable development agenda 
• The importance of research integrity in making evidence accessible 
• Power of synergy in evidence synthesis & synthesis products 
• Evidence translation & implementation 
• Advocating for greater evidence communication & use of evidence 
• From global evidence to local impact

Catherine Spencer, Cochrane's CEO, extends a personal invitation to everyone in the Cochrane community: 

"It was wonderful to unite with the vibrant Cochrane community at our recent Cochrane Colloquium in London. In 2024, rather than hosting individual conferences, we take immense pride in co-hosting the 2nd Global Evidence Summit (GES) alongside some of our esteemed partners. This landmark event is scheduled to take place in Prague, Czech Republic, from 10 - 13 September with Satellite meetings on the 9 September.

We extend a warm and enthusiastic invitation to all our Cochrane members and supporters to mark these dates in their calendars and join us for what promises to be an extraordinary gathering of global minds. The GES serves as a pivotal platform for discussions spanning critical issues across various sectors, including health, education, social justice, the environment, and climate change.

Attending the GES will undoubtedly be of great benefit to our Cochrane community, fostering synergies and facilitating knowledge sharing within the global evidence community. I extend an invitation to explore the website, mark your calendars, and begin contemplating abstract submissions. Let's prepare to unite for #GES2024, actively shaping a future anchored in evidence-synthesis and collaborative efforts."

• Visit the newly launched GES website
• Subscribe to the GES 2024 newsletter

 

Thursday, December 21, 2023

阻止儿童和青少年使用电子烟的干预措施有效吗？ 关键信息 目前尚未有发表的随机对照试验评估预防或停止儿童和青少年使用电子烟的干预措施的影响。然而，我们确实找到了22个正在进行的此类研究，它们似乎符合本未来更新本综述的条件，这可能会提供更多的答案。 我们想要研究什么？ 我们想探究干预措施在预防或终止（即停止）儿童和/或青少年使用电子烟方面的有效性。我们还想知道这些干预措施对儿童和/或青少年使用烟草的效果，以及干预措施是否对儿童和/或青少年的健康或提供干预措施的组织产生任何影响。 我们做了哪些工作？ 我们从随机对照试验（一种受试者被随机分配到两个或多个治疗组中的一组的研究类型）中检索了所有可用证据来回答综述问题。 我们发现了什么？ 我们在2023年5月1日进行研究检索，但并未发现已发表研究。然而，我们发现了22项正在进行的研究，它们可能会被纳入综述的未来更新中。鉴于我们没有发现可纳入的研究，我们并不知道干预措施在预防或停止儿童和/或青少年使用电子烟方面的有效性。 证据的时效性如何？ 证据收录截止至2023年5月1日。 这是一项实时系统综述。我们在每个月检索新证据，并在检索到相关新证据时更新综述。欲了解本系统综述现状，请检索Cochrane系统综述数据库。 如果您发现此证据有帮助，请考虑向 Cochrane 捐款。我们是一家慈善机构，提供可获取的证据来帮助人们做出健康和护理决定。捐赠 作...

Specifications: Permanent – Full Time
Salary:  £60,000 per Annum  
Location: (Remote – Flexible) Ideally based in UK, Germany and Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries.
Closing date: 01 January 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

This role will lead the Membership, Learning & Support department in providing strategically-focussed services, providing intelligent pathways for people to get involved through membership, communicating and engaging with them in innovative ways to strengthen and develop their relationship with Cochrane, shaping and offering high quality learning experiences, and supporting people with their enquiries.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally.  
• A flexible work environment  
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply
• The deadline to receive your application is 1st Jan, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Wednesday, December 13, 2023 Category: Jobs

他汀类药物可以帮助不需要进行透析的慢性肾病患者降低死亡风险 研究问题是什么？ 慢性肾脏疾病（chronic kidney disease, CKD）成年患者有心血管事件的风险高，血清胆固醇和甘油三酯升高，这是导致心血管疾病的一个因素。他汀类药物治疗有助于降低坏胆固醇（低密度脂蛋白）的水平；除了降低胆固醇外，还具有心血管保护作用。对于不需要透析的患者，他汀类药物治疗已被证明可以减少死亡和心血管事件。尽管如此，对这一人群的研究显示，尚不明确对中风、肾衰竭和诸如肌肉损伤（横纹肌溶解）等危害的影响。 我们做了什么？ 我们研究了2023年10月4日前发表的62项研究，这些研究是关于对超过5万名不需要进行透析治疗的CKD患者使用他汀类药物。本综述是实时系统综述。每三个月将进行一次新证据的检索，并相应地更新综述。 我们发现了什么？ 我们发现，与安慰剂相比，他汀类药物治疗减少了死亡和主要心脏相关事件，接受他汀类药物治疗的13名患者中有1人避免了心脏相关事件，26名患者中有1人避免了死亡。他汀类药物治疗可能对中风和肾衰竭（当人们从透析或肾移植中获益时）几乎没有效果或无效果。他汀类药物治疗的益处在CKD患者中也很明显，但在心脏病患者中则不然。他汀类药物有一些潜在的危害；然而，我们发现其对癌症、肝功能或因不良事件而退出治疗可能没有影响。在这些研究中，关于肌肉损伤的报告有限。 对于治疗不需要进行透析的C...

口服或鼻用类固醇治疗儿童中耳炎积液(OME或“胶耳”) 关键信息 口服片剂或糖浆形式的类固醇可能对胶耳患儿的听力和生活质量影响很小或没有影响。类固醇可能会减少 6 至 12 个月后患胶耳的儿童数量，但我们不确定这种减少的幅度有多大。 使用类固醇鼻腔喷雾剂对听力或生活质量也可能影响不大，尽管证据并不那么充分。目前还不清楚长期随访后鼻用类固醇是否会影响患胶耳的儿童数量。 由于缺乏稳健证据，很难知道有多少人可能因这些治疗而受到伤害。然而，当口服类固醇用于治疗其他疾病并长期使用时，可能会引起骨质流失等副作用。在决定是否使用这些治疗方法时，应该考虑到这种潜在的伤害。 什么是OME？ 胶耳或分泌性中耳炎（Otitis media with effusion, OME）是影响幼儿的一种常见疾病。液体积聚在中耳，会导致听力受损。由于听力不佳，儿童可能会出现行为障碍和语言发育迟缓。 如何治疗OME？ 大多数时候，OME不需要任何治疗，症状会随着时间的推移而改善。对于患有持续性OME的儿童，人们已经探索了不同的治疗方法，包括药物或手术。 我们想知道什么？ 我们想知道，对于患有OME的儿童来说，类固醇是否比安慰剂（假治疗或仿真治疗）或不治疗更好。 我们也想看看服用类固醇是否会产生任何不良反应。 我们做了什么？ 我们检索了针对OME患儿的类固醇片剂治疗或鼻腔喷雾剂与安慰剂或无治疗进行比较的研究。我们对研...

Tuesday, December 12, 2023

酶替代疗法（ERT）对晚发型庞贝氏症（LOPD）患者有什么影响? 关键信息 ·晚发型庞贝氏症（Late-onset Pompe disease, LOPD）是一种罕见的疾病，会使患者随着时间的推移而变得更加不适。酶替代疗法（Enzyme replacement therapy, ERT）有助于减缓疾病的进展。 ·与安慰剂（一种无效或“假”的药物）相比，alglucosidase alfa（一种ERT）可能会改善晚发型庞贝氏症（LOPD）患者疾病进展的某些方面。 ·未来的研究应尽可能对受试者进行长达数年的监测，以更好地了解治疗的长期效果。 什么是晚发型庞贝氏症（LOPD）？ LOPD是一种罕见的遗传性疾病，会导致肌无力、呼吸困难和预期寿命缩短。它是由于缺乏酸性α-葡萄糖苷酶（acid alpha-glucosidase, GAA）引起的。酶是帮助加快体内化学反应的蛋白质。它们对于呼吸、消化食物、肌肉功能和许多其他过程都至关重要。任何年龄的人都可能开始出现LOPD症状。患有LOPD的人体内仍保留着一些残留的酶活性，这意味着他们体内产生的酶仍在进行一些预期的工作。 如何治疗LOPD？ LOPD的治疗方法是通过静脉输注一种名为“重组人酸阿糖苷酶α”的替代酶。这种酶替代疗法（ERT）有两种类型——alglucosidase alfa和avalglucosidase alfa——它们都是已获...

与传统的28天周期激素类避孕药相比，延长服用超过28天以上的复方激素类避孕药效果更佳。 传统的复方激素类避孕药（combined hormonal contraceptives，CHCs），包括口服避孕药、透皮贴剂和阴道环，每天使用，21天为一个周期，随后一周不使用激素类药物。而在不服用激素的一周，会发生撤退性出血。近年来，还开发了其他复方激素避孕药的方法：其中包括连续服用CHCs超过28天，还有一些治疗方案是在使用CHC时根据计划偶尔停药几天，而另一些方案则没有停药。延迟或消除激素药物使用中断已成为妇女避免每月发生撤退性出血的一种流行疗法，因此我们对这些新的方案与传统的CHC给药方案进行了比较。我们检索了所有关于这个问题的随机对照试验，发现有12项研究符合我们的纳入标准。从出血率、停药率和报告满意度判断，连续或延长周期治疗方案与传统治疗方案相似。但这些研究样本量太小，无法对疗效、罕见不良事件和安全性得出确切结论。延长周期（超过28天）或连续给药似乎是CHC使用的合理方法。 如果您发现此证据有帮助，请考虑向 Cochrane 捐款。我们是一家慈善机构，提供可获取的证据来帮助人们做出健康和护理决定。捐赠 作者结论:  2014年的更新增加了4项试验，但结论没有改变。现有的随机对照试验比较了连续或延长周期的CHCs(大于28天的活性复方激素)与传统的周期给药(21天的活性激...

内窥镜鼻窦手术（即使用一根细长管插入鼻窦的手术）是否有助于治疗囊性纤维化（cystic fibrosis, CF）患者的鼻息肉（鼻腔内的柔软生长物，称为息肉）？ 关键信息 与单独进行鼻腔冲洗相比，我们还不确定鼻腔冲洗与内窥镜鼻窦手术干预是否能改善症状和肺功能，或减少对抗生素的需求。 手术期间发生过一次出血，但在手术过程中得到了纠正，没有造成进一步的后果。 什么是囊性纤维化？ 囊性纤维化是一种遗传疾病，会影响肺、鼻子、鼻窦和身体的其他器官。人体会产生难以清除的粘稠粘液，并引发炎症。由于粘稠的粘液和炎症，许多患有囊性纤维化的成人和儿童的鼻腔和鼻窦都会长息肉。 息肉会导致更多的肺部感染，并降低生活质量。 囊性纤维化鼻息肉如何治疗？ 内窥镜鼻窦手术的目的是打开堵塞的鼻窦，以改善呼吸，使粘液更容易清除。该手术有一些副作用（出血和鼻窦损伤）。 药物治疗包括多种药物（吸入和吞咽），如抗生素、类固醇和湿氧吸入药物。盐水也可用于鼻塞。目前有一类新药，称为囊性纤维化跨膜传导调节剂（cystic fibrosis transmembrane conductance regulator, CFTR）调节剂；这些药物能够纠正CFTR蛋白的基本缺陷，但尚不清楚它们会对鼻息肉产生什么影响。 我们想发现什么？ 单独使用鼻窦内窥镜手术或与药物治疗联合使用是否比单独药物治疗更能改善囊性纤维化患者的生活质量和肺功能而...

Wednesday, December 6, 2023

提高和维持中低收入国家疫苗接种率的干预措施 本系统综述的目的是什么？ 本Cochrane系统综述的目的是评价不同策略对于增加低收入和中等收入国家儿童接种疫苗以预防疾病感染的影响。Cochrane的研究人员收集并分析了所有相关的研究来回答这个问题，发现了41项相关的研究。 这些改善儿童疫苗接种工作的策略有效吗？ 中低收入国家仍有数百万儿童死于本可通过疫苗预防的疾病，部分原因是这些国家接种疫苗的儿童数量仍然很少。各国政府和其他机构尝试了不同的策略来增加接种疫苗的儿童数量。 本系统综述研究了什么？ 我们评价了旨在提高五岁以下儿童疫苗接种率的所有干预措施。这些干预措施包括针对照料者（父母/监护人）、护理提供者、社区、卫生系统或以上任意组合的干预措施。 本系统综述的主要研究结果是什么？ 综述作者发现了来自阿富汗、中国、科特迪瓦、埃塞俄比亚、格鲁吉亚、加纳、危地马拉、洪都拉斯、印度、印度尼西亚、肯尼亚、马里、墨西哥、尼泊尔、尼加拉瓜、尼日利亚、巴基斯坦、卢旺达和津巴布韦的41项相关研究。这些研究涉及100747名受试者。他们将接受这些策略的人与仅接受常规医疗服务的人进行了比较。研究结果如下： - 单独的免疫外展或与非金钱激励或健康教育相结合 可能会提高五岁以下儿童的全面疫苗接种率。 - 健康教育 可能会使更多儿童接受三剂白喉-破伤风-百日咳疫苗（diphtheria-tetanus-pert...

小切口对比标准胸前完全切口术进行心脏主动脉瓣置换术 关键信息 - 目前尚无足够高质量的证据来回答，在进行主动脉瓣膜置换手术时，是通过传统的完整胸骨切口，还是通过较小的胸骨顶部切口更为适当。 - 心脏手术出现的重要合并症在两组中均不常见。 什么是主动脉置换术？ 主动脉瓣置换术是更换心脏瓣膜的常见手术。需要进行主动脉瓣膜置换手术的原因包括瓣膜无法正确打开或关闭，这可能会随着年龄增长而发生。患有主动脉瓣疾病的人可能会出现胸痛、呼吸困难、晕倒或猝死。 如何进行主动脉置换术？ 进行此手术最常见的方式是打开整个胸骨。另一种方法涉及一个较小的“钥匙孔”型切口，只切开胸骨的一小部分。通过这种方式进行手术会使切口更小，但也会使手术更具挑战性，因为更难以看到、接触到心脏。尽管从外表上看起来切口更小，但这可能会使手术时间更长，安全性更低。 我们想要研究什么？ 我们想了解，相比于常用的完整切开胸骨（全胸骨切开术），在成年人进行主动脉瓣置换手术时，采用较微创手术（有限胸骨切开术）是否更好。我们想要确定两种方法是否同样安全和有效。 我们做了什么？ 我们更新了先前撰写过此主题的综述。我们检索了对比使用有限胸骨切口手术和完全胸骨切口手术进行成人主动脉瓣膜置换手术的研究。我们比较并总结了研究结果，并根据研究方法、样本规模等因素对证据的可信度进行评级。 我们发现了什么？ 我们发现了14项研究，涵盖了来自欧洲、俄罗斯...

抗生素治疗儿童急性中耳感染（急性中耳炎） 关键信息 在高收入国家，大多数患有急性中耳炎（acute otitis media, AOM）的儿童会自然康复且无并发症，并且与安慰剂相比，抗生素对早期疼痛没有效益，只在后续几天里对疼痛有轻微的益处。 抗生素的任何益处必须权衡其可能的危害：每14名接受抗生素治疗的儿童中，就有一名儿童出现不良事件（如呕吐、腹泻或皮疹），而如果不给予抗生素，就不会出现这些不良事件。 对于高收入国家大多数疾病程度轻的儿童来说，等待观察方法似乎是合理的。 什么是急性中耳炎？ 急性中耳感染（AOM）是婴儿早期和儿童期最常见的疾病之一，会引起疼痛和一般疾病症状，例如发烧、烦躁以及喂食和睡眠问题。 我们想研究什么？ 我们想了解抗生素是否能有效缓解AOM儿童的体征和症状。 我们做了什么？ 我们检索了一些研究，比较抗生素与安慰剂或等待观察（观察性等待）对1个月至15岁AOM儿童的有效性。我们经过比较并总结这些研究的结果，及根据研究方法和规模等因素，评价这些证据的质量。 我们发现了什么？ 我们发现，与安慰剂相比，抗生素并没有减少24小时内出现疼痛儿童的数量（此时60%的儿童已恢复或有改善），仅略微减少了随后几天出现疼痛的儿童数量，并且也没有减少儿童晚期AOM复发的数量。然而，与安慰剂相比，抗生素确实略微减少了鼓膜穿孔（破裂）和未受影响的耳朵出现急性中耳炎的数量。抗生素减少了...

使用皮质类固醇预防带状疱疹后神经痛的效果有哪些？ 关键信息 •我们不知道在带状疱疹感染急性期口服皮质类固醇对预防带状疱疹后神经痛是否有效。 •口服或肌肉组织注射皮质类固醇对急性带状疱疹患者不良反应的发生风险几乎没有差异。 什么是带状疱疹后神经痛？ 带状疱疹后神经痛（postherpetic neuralgia, PHN）是带状疱疹发作后在出疹部位出现的一种疼痛症状。带状疱疹后神经痛可能会一直持续到患者死亡，并对生活质量和医疗资源使用产生重大影响。许多带状疱疹后神经痛患者发现治疗效果甚微或根本没有效果。因此，人们开始关注如何阻止带状疱疹后遗神经痛的发展。一些研究人员认为，出现带状疱疹后神经痛的人血液中的水痘-带状疱疹病毒水平高于病毒休眠时通常所发现的低水平，这导致了持续的炎症。皮质类固醇具有强大的抗炎作用，可以最大限度地减少神经损伤，从而缓解带状疱疹疼痛，预防带状疱疹后神经痛。 我们想知道什么？ 我们想知道在带状疱疹感染期紧急服用皮质类固醇（出疹一周内）是否能有效预防带状疱疹后神经痛。我们纳入了将皮质类固醇与未经治疗或安慰剂进行比较的研究，但未纳入与其他治疗方法进行比较的研究。我们还纳入了将皮质类固醇联合常规治疗与安慰剂联合常规治疗进行比较的试验。 我们做了什么？ 我们检索了所有描述了皮质类固醇对预防急性带状疱疹感染后的带状疱疹后神经痛的效果的随机对照临床试验。考虑到研究规模和研究...

英夫利西单抗用于治疗活动性克罗恩病 关键信息 – 英夫利西单抗与嘌呤类似物（硫唑嘌呤或6-巯基嘌呤）一起使用可能比单独使用嘌呤类似物更有效地缓解克罗恩病。也可能更好地改善症状。这两种治疗方法在安全性方面可能相似。 –单独使用英夫利西单抗可能比单独使用嘌呤类似物更有效地缓解克隆氏症并改善症状。这两种治疗方法在安全性方面可能相似。 –在缓解克隆氏症和改善症状方面，英夫利西单抗可能与生物相似药一样有效。这两种治疗方法在安全性方面可能相似。英夫利西单抗生物相似药是一种生物药物（包含利用活细胞或生物体产生的物质），与英夫利西单抗的原品牌高度相似。 什么是克罗恩病？ 克罗病是一种终生发炎性疾病，会影响肠道的任何部位。常见症状包括血便、腹泻、胃痛、发烧、体重减轻和疲倦。我们不知道克罗恩病的确切原因，但它可能是基因、免疫系统问题（保护身体免受感染）、肠道细菌和环境中某些物质的综合作用。 已知克罗恩病尚无治疗方法，但通常可以通过药物来控制症状，例如皮质类固醇和免疫系统药物，有时还需要手术。英夫利西单抗是克罗恩病药物的一种，称为生物药物。 大多数克罗恩病患者有时会出现症状，有时则症状得到控制。当他们出现症状时，称为活动性疾病。当他们的症状得到控制时，称为缓解。 我们想知道什么? 我们想了解英夫利西单抗与其他药物或虚拟治疗（安慰剂）相比如何使缓解克罗恩病或改善症状。我们也想了解与其他药物相比，英夫利昔...

两种肾结石治疗方案的比较 什么是肾结石？ 肾结石是含钙物质的集合体，质地通常很硬，可以在一个或两个肾脏中形成。当某些高浓度的矿物质在泌尿道中形成晶体时，就会形成肾结石。这些石头可以小如沙粒，也可以大如豌豆。在极少数情况下，他们可以像高尔夫球一样大。小肾结石可能不会引起症状或剧烈疼痛。而较大的结石会让尿液难以从肾脏排出。 如何治疗肾结石？ 患有大肾结石的人通常需要治疗。有两种常见方法可以治疗，分别称为经皮肾镜取石术（percutaneous nephrolithotomy, PCNL）和逆行肾内手术（retrograde intrarenal surgery, RIRS）。PCNL即将一根小管从皮肤插入肾脏，然后使用不同的器械打碎并取出结石。RIRS是将一根长内视镜穿过尿道（连接膀胱和体外的管道）和输尿管（连接膀胱和肾脏的管道）放入肾脏，然后使用不同的器械将其打碎并取出结石。目前尚不清楚这两种治疗方法比较的结果。 我们想知道什么？ 我们想知道PCNL在治疗肾结石方面是否比RIRS更好。我们主要关注以下结果。 • 彻底清除结石与否 • 严重并发症的风险 • 需要另一种手术来清除结石 • 计划外就诊 • 住院时长 • 输尿管变窄或损伤的风险 • 生活质量 我们做了什么？ 我们检索了对患有任何大小、位于肾脏的任何部位的肾结石的成年人采用PCNL与RIRS进行比较的研究。我们比较和总结了研...

Monday, December 4, 2023

Cochrane Crowd is a global community of volunteers who are helping to classify the research needed to support informed decision-making about health care. Cochrane Mexico recently hosted its third screening challenge that helped introduce students to randomized control trials and evidence assessment. This event not only fostered the value of evidence synthesis among students but also made a significant contribution to ongoing global research efforts. 


The job of the Cochrane Crowd community is to review descriptions of research studies to identify and classify randomized controlled trials (RCTs), a type of study that is considered the gold standard for clinical trials. Reports of RCTs are then fed into Cochrane’s Central Register of Controlled Trials, helping Cochrane authors and other systematic reviewers quickly find the evidence they need to determine whether a treatment works, or whether a diagnostic test is accurate.

Cochrane Mexico student event involved 31 universities  

The Cochrane Mexico Associated Centre at Sinaloa’s Pediatric Hospital,  the Autonomous University of Sinaloa, and the Mexican Association of Doctors in Training hosted their third Cochrane Crowd challenge. The first two challenges (held in 2018 and 2022) were limited to the Autonomous University of Sinaloa's students. This year, all Mexican medical schools were invited to participate and two students per university were selected.

59 students from 31 universities virtually participated, conducting 65,958 classifications in Cochrane Crowd in 24 hours. In total 3093 randomized clinical trials were identified. 59 medical students completed the 24 hours with more than 1000 classifications received Cochrane Memberships. First place was Pavel Martínez, from the Autonomous University of Chihuahua, who made 1104 classifications and had an accuracy of 97%.

Giordano Perez-Gaxiola, director of Cochrane Mexico and key challenge organizer, says: “Cochrane Crowd is a great introduction to systematic reviews and randomized control trials for students. Having students participate in a time-limited challenge is a fun way to engage students and was simple for us to set-up. The students exceeded all our expectations this year and we are so proud of them! Many of the students enjoyed it so much and could see results of their efforts for global health research that they are continuing to do screening on Cochrane Crowd!”

Anyone can join Cochrane Crowd and no previous experience is necessary

“Cochrane sends its thanks to all those involved in this citizen scientist challenge using Cochrane Crowd – what an amazing achievement in just 24 hours!” says Anna Noel-Storr, Cochrane’s Evidence Pipeline Lead. “We hope these students inspire everyone to give Cochrane Crowd a try. From medical students, to clinicians, to anyone with an interest in health research – being a part of Cochrane Crowd can help individuals develop skills in understanding health evidence while collectively contributing to global research efforts.” 

Has Cochrane Mexico inspired you to organise a Cochrane Crowd challenge at your workplace or university? If so, please get in contact and we will support you to get one up and running: crowd@cochrane.org

• Join Cochrane Crowd - everyone is welcome!
• If you teach evidence-based medicine, check out Cochrane Classmate, the platform we run challenges on.

Friday, December 1, 2023